@article{d532a07ddcbe49cfa4c4b98627c2ec9b,
title = "Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder",
abstract = "REM sleep behavior disorder (RBD) is strongly associated with development of Parkinson{\textquoteright}s Disease and other α-synuclein-related disorders. Dopamine transporter (DAT) binding deficit predicts conversion to α-synuclein-related disorders in individuals with RBD. In turn, identifying which individuals with RBD have the highest likelihood of having abnormal DAT binding would be useful. The objective of this analysis was to examine if there are basic clinical predictors of DAT deficit in RBD. Participants referred for inclusion in the RBD cohort of the Parkinson Progression Markers Initiative were included. Assessments at the screening visit including DAT SPECT imaging, physical examination, cognitive function screen, and questionnaire-based non-motor assessment. The group with DAT binding deficit (n = 49) was compared to those without (n = 26). There were no significant differences in demographic or clinical features between the two groups. When recruiting RBD cohorts enriched for high risk of neurodegenerative disorders, our data support the need for objective biomarker assessments.",
author = "{the PPMI Sleep Working Group} and Chahine, {L. M.} and A. Iranzo and A. Fern{\'a}ndez-Arcos and T. Simuni and N. Seedorff and C. Caspell-Garcia and Amara, {A. W.} and C. Comella and B. H{\"o}gl and J. Hamilton and K. Marek and G. Mayer and B. Mollenhauer and R. Postuma and E. Tolosa and C. Trenkwalder and A. Videnovic and W. Oertel and B. Kumar and L. James and G. Nomikos and J. Cedarbaum and M. Yang and M. Brys and V. Irzhevesky and K. Schmidt and N. Jennings and A. Reith and D. Tattersall and M. Sanchez and N. Daegele and C. Min and R. Malkani and J. Peterschmitt and P. Sardi and S. Bozzi and T. Fischer and R. Evans and V. Kiyasova and A. Simen and A. Siderowf",
note = "Funding Information: The authors thank Giovanni Di Bartolomeo (University of Antwerp) for much appreciated assistance in several computations and drawings; furthermore they like to thank the referees, Andrew Hughes Hallett (University of Strathclyde) and participants of seminars at the University of Strathclyde, the University of Bielefeld and CESifo (Munich) for useful suggestions improving the paper. The first author acknowledges the financial support from F.W.O. (Fonds voor Wetenschappelijk Onderzoek Vlaanderen). A previous version of this paper appeared as Research Paper No. 2001-005 of the Faculty of Applied Economics UFSIA-RUCA (University of Antwerp) and as CESifo Working Paper No. 437 (Munich). Publisher Copyright: {\textcopyright} 2019, The Author(s).",
year = "2019",
month = dec,
day = "1",
doi = "10.1038/s41531-018-0073-1",
language = "English (US)",
volume = "5",
journal = "npj Parkinson's Disease",
issn = "2373-8057",
publisher = "Springer Nature",
number = "1",
}